Marquis®
by Boehringer Ingelheim- FDA approved treatment for equine protozoal myeloencephalitis (EPM)
- Kills Sarcocystis neurona to prevent further damage to central nervous system
- Contains the active ingredient ponazuril
- Requires a veterinarian's prescription
- Provided as an oral paste
| Catalog # | Description | Price | Qty | Autoship | CART | FAVORITES |
sc-362888Rx | 4 x 127 g tubes | $1289.09 |
Click product's Autoship icon - choose frequency at Checkout.
Never forget a shipment so you're always stocked.
Saves you 5% on UltraCruz® products.
You manage the frequency or cancellation to fit your needs.
Marquis® is the first FDA approved treatment for equine protozoal myeloencephalitis (EPM).
Equine protozoal myeloencephalitis (EPM) is a common neurologic disease of horses living in the Americas. EPM is caused by the protozoa Sarcocystis neurona and leads to inflammation of the brain and spinal cord, resulting in various neurological deficits in horses such as abnormal gait, stumbling, falling and an inability to rise. The definitive host of EPM is the opossum, which sheds infective sporocysts of S. neurona that infect horses.
Marquis® is an antiprotozoal oral paste approved by the FDA for the treatment of horses with EPM. It contains the active ingredient ponazuril which crosses the blood/brain barrier to reach the central nervous system. Once it has reached the central nervous system, ponazuril works to kill S. neurona to prevent the parasite from causing further damage.
Each package of Marquis® contains sufficient paste to treat one 1200 lb horse for 28 days. The safe use of Marquis® in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.
Supplied as a package of four 127 g tubes. Please note that this product requires a veterinarian's prescription for purchase.
